Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Photosynthetic characteristics of Cuscuta japonica and its hosts during parasitization and after detachment].

Ying yong sheng tai xue bao = The journal of applied ecology·2007
Same author

Hepatoma-derived growth factor binds DNA through the N-terminal PWWP domain.

BMC molecular biology·2007
Same author

[Evaluation of bubble oxygen inhalators' performances and an investigation on their solutions for improvement].

Zhongguo yi liao qi xie za zhi = Chinese journal of medical instrumentation·2007
Same author

Relaxation mechanisms of neferine on the rabbit corpus cavernosum tissue in vitro.

Asian journal of andrology·2007
Same author

[Effect of niacin on HDL-induced cholesterol efflux and LXRalpha expression in adipocytes of hypercholesterolemic rabbits].

Zhonghua xin xue guan bing za zhi·2007
Same author

Total synthesis of (+/-)-communesin F.

Journal of the American Chemical Society·2007
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

On assessing bioequivalence using genomic data with model misspecification.

Qingshu Lu1, Siu-Keung Tse, Shein-Chung Chow

  • 1Department of Statistics and Finance, University of Science and Technology of China, Anhui, China.

Journal of Biopharmaceutical Statistics
|February 26, 2010
PubMed
Summary
This summary is machine-generated.

This study reveals that using a linear model for pharmacokinetic and genomic data can impact bioequivalence assessment when the true relationship is quadratic. Misspecification affects statistical power and required sample sizes for average bioequivalence testing.

More Related Videos

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
10:17

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations

Published on: November 3, 2010

Related Experiment Videos

Last Updated: Jun 15, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
10:17

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations

Published on: November 3, 2010

Area of Science:

  • Pharmacometrics
  • Genomics
  • Biostatistics

Background:

  • Bioequivalence assessment is crucial for drug development.
  • Genomic data integration offers novel insights into drug response.
  • Nonlinear relationships between pharmacokinetic (PK) and genomic data can exist.

Purpose of the Study:

  • To evaluate the impact of a misspecified linear model on bioequivalence assessment when the true PK-genomic relationship is quadratic.
  • To compare the power function and sample size requirements under true versus misspecified models for average bioequivalence (ABE).

Main Methods:

  • The study assumes a true quadratic relationship between PK and genomic data.
  • A misspecified linear model is used for bioequivalence testing.
  • A numerical study is conducted to analyze the effects of model misspecification.

Main Results:

  • The use of a linear model instead of the true quadratic model leads to altered power functions for ABE tests.
  • Misspecification of the PK-genomic relationship affects the sample size needed for bioequivalence studies.
  • The extent of these effects is explored through numerical simulations.

Conclusions:

  • Model misspecification in the relationship between PK and genomic data can significantly influence bioequivalence assessment outcomes.
  • Accurate modeling of PK-genomic interactions is essential for reliable bioequivalence testing.
  • Further research should investigate robust methods for bioequivalence assessment with complex PK-genomic relationships.